ReviewEuropean journal of clinical investigation2026
Revisiting tricuspid regurgitation: Historical insights and emerging research perspectives.
Review in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Novel Minimally Invasive Porcine Model of Functional Tricuspid Regurgitation.Journal of cardiovascular development and disease · 2026Article
- Revisiting tricuspid regurgitation: Historical insights and emerging research perspectives.European journal of clinical investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTricuspid regurgitation (TR), defined as the failure of proper leaflet coaptation during systole, is a common but often underrecognized valvular disorder. TR continues to rise, primarily due to population aging and the broader application of advanced diagnostic imaging techniques. Recent studies have established a clear association between TR and increased morbidity and mortality, thereby challenging its historical perception as a benign condition.
methodsThe development of novel interventional therapies, combined with enhanced insight into the pathophysiology of right-sided heart failure, has prompted a shift towards earlier diagnosis and more proactive clinical management.
aimSeveral gaps between novel scientific advancements and clinical translation still make this disease deserving of further attention. DISCUSSION AND
conclusionIn this review, we examine the most recent advances in understanding TR, which have enabled improved segmentation of affected patient populations. This progress has made it possible to identify key prognostic markers-particularly those related to disease progression-allowing for more accurate risk stratification and significantly more personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.